Voxelwise analysis of conventional magnetic resonance imaging to predict future disability in early relapsing-remitting multiple sclerosis

被引:10
|
作者
Wybrecht, Delphine [1 ,2 ]
Reuter, Francoise [1 ,3 ]
Zaaraoui, Wafaa [1 ]
Faivre, Anthony [1 ,2 ]
Crespy, Lydie [1 ,3 ]
Rico, Audrey [1 ,3 ]
Malikova, Irina [1 ,3 ]
Confort-Gouny, Sylviane [1 ]
Soulier, Elisabeth [1 ]
Cozzone, Patrick J. [1 ]
Pelletier, Jean [1 ,3 ]
Ranjeva, Jean-Philippe [1 ]
Audoin, Bertrand [1 ,3 ]
机构
[1] Aix Marseille Univ, CEMEREM, UMR 7339, Marseille, France
[2] Hop Instruct Armees St Anne, Serv Neurol, F-83800 Toulon, France
[3] Hop Enfants La Timone, APHM, Serv Neurol, Marseille, France
关键词
multiple sclerosis; MRI; cognition; disability; prediction; CIS; CLINICALLY ISOLATED SYNDROMES; EARLY COGNITIVE IMPAIRMENT; 10-YEAR FOLLOW-UP; LESION LOCATION; CALLOSAL ATROPHY; BRAIN MRI; ABNORMALITIES; DEFICITS; ONSET;
D O I
10.1177/1352458512442991
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: The ability of conventional magnetic resonance imaging (MRI) to predict subsequent physical disability and cognitive deterioration after a clinically isolated syndrome (CIS) is weak. Objectives: We aimed to investigate whether conventional MRI changes over 1 year could predict cognitive and physical disability 5 years later in CIS. We performed analyses using a global approach (T-2 lesion load, number of T-2 lesions), but also a topographic approach. Methods: This study included 38 patients with a CIS. At inclusion, 10 out of 38 patients fulfilled the 2010 revised McDonald's criteria for the diagnosis of multiple sclerosis. Expanded Disability Status Scale (EDSS) evaluation was performed at baseline, year 1 and year 5, and cognitive evaluation at baseline and year 5.T-2-weighted MRI was performed at baseline and year 1. We used voxelwise analysis to analyse the predictive value of lesions location for subsequent disability. Results: Using the global approach, no correlation was found between MRI and clinical data. The occurrence or growth of new lesions in the brainstem was correlated with EDSS changes over the 5 years of follow-up. The occurrence or growth of new lesions in cerebellum, thalami, corpus callosum and frontal lobes over 1 year was correlated with cognitive impairment at 5 years. Conclusion: The assessment of lesion location at the first stage of multiple sclerosis may be of value to predict future clinical disability.
引用
收藏
页码:1585 / 1591
页数:7
相关论文
共 50 条
  • [41] Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis A 5-year longitudinal study
    Horakova, Dana
    Dwyer, Michael G.
    Havrdova, Eva
    Cox, Jennifer L.
    Dolezal, Ondrej
    Bergsland, Niels
    Rimes, Brett
    Seidl, Zdenek
    Vaneckova, Manuela
    Zivadinov, Robert
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 282 (1-2) : 112 - 119
  • [42] Lesion-Specific Metabolic Alterations in Relapsing-Remitting Multiple Sclerosis Via 7 T Magnetic Resonance Spectroscopic Imaging
    Lipka, Alexandra
    Niess, Eva
    Dal-Bianco, Assunta
    Hangel, Gilbert J.
    Rommer, Paulus S.
    Strasser, Bernhard
    Motyka, Stanislav
    Hingerl, Lukas
    Berger, Thomas
    Hnilicova, Petra
    Kantorova, Ema
    Leutmezer, Fritz
    Kurca, Egon
    Gruber, Stephan
    Trattnig, Siegfried
    Bogner, Wolfgang
    INVESTIGATIVE RADIOLOGY, 2023, 58 (02) : 156 - 165
  • [43] The prognostic value of initial relapses on the evolution of disability in patients with relapsing-remitting multiple sclerosis
    Binquet, C.
    Quantin, C.
    Le Teuff, G.
    Pagliano, J. F.
    Abrahamowicz, M.
    Moreau, T.
    NEUROEPIDEMIOLOGY, 2006, 27 (01) : 45 - 54
  • [44] Segmented corpus callosum diffusivity correlates with the Expanded Disability Status Scale score in the early stages of relapsing-remitting multiple sclerosis
    Rimkus, Carolina de Medeiros
    Junqueira, Thiago de Faria
    Callegaro, Dagoberto
    Garcia Otaduy, Maria Concepcion
    Leite, Claudia da Costa
    CLINICS, 2013, 68 (08) : 1115 - 1120
  • [45] Microstructural analysis of verbal fluency performance in relapsing-remitting multiple sclerosis based on the impact of disability level
    Altun, Melis Buse
    Oge-Dasdogen, Ozlem
    Tutuncu, Melih
    APPLIED NEUROPSYCHOLOGY-ADULT, 2024,
  • [46] Measuring productivity loss in early relapsing-remitting multiple sclerosis
    Sainz de la Maza, Susana
    Maurino, Jorge
    Borges, Monica
    Martin-Martinez, Jesus
    Sotoca, Javier
    Alonso, Ana
    Caminero, Ana B.
    Borrega, Laura
    Sanchez-Menoyo, Jose L.
    Barrero-Hernandez, Francisco J.
    Calles, Carmen
    Brieva, Luis
    Blasco, Maria R.
    Dotor Garcia-Soto, Julio
    del Campo-Amigo, Maria
    Navarro-Canto, Laura
    Aguera, Eduardo
    Garces, Moises
    Carmona, Olga
    Gabaldon-Torres, Laura
    Forero, Lucia
    Hervas, Mariona
    Ruiz de Alda, Lucia
    Gomez-Ballesteros, Rocio
    Castillo-Trivino, Tamara
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 58
  • [47] Cognitive Impairment in Patients with Early Relapsing-Remitting Multiple Sclerosis
    Keklikoglu, Hava Doenmez
    Yoldas, Tahir Kurtulus
    Zengin, Oezkan
    Banu Solak, Elif
    Keskin, Selda
    NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, 2010, 47 (02): : 88 - 90
  • [48] Progressive grey matter atrophy in clinically early relapsing-remitting multiple sclerosis
    Chard, DT
    Griffin, CM
    Rashid, W
    Davies, GR
    Altmann, DR
    Kapoor, R
    Barker, GJ
    Thompson, AJ
    Miller, DH
    MULTIPLE SCLEROSIS JOURNAL, 2004, 10 (04) : 387 - 391
  • [49] Impact of the McDonald Criteria 2017 on Early Diagnosis of Relapsing-Remitting Multiple Sclerosis
    Schwenkenbecher, Philipp
    Wurster, Ulrich
    Konen, Franz Felix
    Gingele, Stefan
    Suehs, Kurt-Wolfram
    Wattjes, Mike P.
    Stangel, Martin
    Skripuletz, Thomas
    FRONTIERS IN NEUROLOGY, 2019, 10
  • [50] Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
    S. Grahl
    M. Bussas
    B. Wiestler
    P. Eichinger
    C. Gaser
    J. Kirschke
    C. Zimmer
    A. Berthele
    B. Hemmer
    M. Mühlau
    Neurotherapeutics, 2021, 18 : 2589 - 2597